SEARCH RESULTS FOR:
Danny Foong
GENERAL MANAGER, ARKEMA SOUTHEAST ASIA
Arkema updates GBR on its investments in Singapore.
Law Gee Yong
DIRECTOR OF POLICY & PLANNING DEPARTMENT, ENERGY MARKET AUTHORITY
The Energy Market Authority’s (EMA) main goals are to ensure a reliable and secure energy supply, promote effective competition in the energy market and develop a dynamic energy sector in Singapore.
Conrad Karageorge
CEO, AMANI GOLD
MACIG 2022
Amani Gold updates GBR on progress at its Giro gold project in DRC.
Doug Morrison
PRESIDENT & CEO, CENTRE FOR EXCELLENCE IN MINING INNOVATION (CEMI)
Centre for Excellence in Mining Innovation (CEMI) explains how innovation and the implementation of new processes and technologies in the mining sector are vital for future society.
Oliver Dallaway
DIRECTOR DRC, AFRICAN MINING SERVICES (AMS)
MACIG 2022
AMS comments on serving mines and mining contractors in the DRC.
Candice Long
PRESIDENT – US INFECTIOUS DISEASES & VACCINES, JANSSEN PHARMACEUTICALS
"In vaccines, we are progressing late-stage programs of break-through vaccines against diseases where vaccines are not currently available, such as RSV and multidrug resistant bacterial infections, including ExPEC and Staphylococcus aureus."
Joe Panetta
PRESIDENT & CEO, BIOCOM CALIFORNIA
"We experienced explosive growth across the state and consequently adopted a new name: Biocom California."
Renaud Adams
PRESIDENT & CEO, NEW GOLD INC.
New Gold updates GBR on progress at its Rainy River and New Afton mines
Andrew Taylor
PRESIDENT, GROWTH MARKETS, (ASIA, MIDDLE EAST, AFRICA, AND LATIN AMERICA) TATE & LYLE
Tate & Lyle is now transformed into a purpose-led, growth-focused global food and beverage solutions business, serving faster growing specialty markets.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
